. (2016). Synthesis and preliminary evaluation of 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones as angiogenesis inhibitors. Bioorganic and Medicinal Chemistry Letters, 26 (7), 1813-1816. Synthesis and preliminary evaluation of 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones as angiogenesis inhibitors Abstract Sunitinib (Sutent®) is a receptor tyrosine kinase (RTK) and angiogenesis inhibitor approved for the treatment of renal cell carcinomas, gastrointestinal stromal tumours and pancreatic neuroendocrine tumours. A key structural motif retained throughout medicinal chemistry efforts during sunitinib's development was the indoline-2-one group. In the search for new anti-angiogenic scaffolds, we previously reported that nonindoline-2-one-based derivatives of semaxanib (SU5416, a structurally simpler sunitinib predecessor that underwent Phase III trials) are active as angiogenesis inhibitors, indicating that the group is not essential for activity. This Letter describes the synthesis and structure-activity relationships of another class of nonindoline-2-one angiogenesis inhibitors related to sunitinib/semaxanib; the 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones. A focussed library of 19 analogues was prepared using a simple novel process, wherein commercially available substituted arylacetic acids activated with an amide coupling reagent (HBTU) were reacted with the potassium salt of 3,5-dimethyl-1H-pyrrole-2-carbaldehyde in one-pot. Screening of the library using a cell-based endothelial tube formation assay identified 6 compounds with anti-angiogenesis activity. Two of the compounds were advanced to the more physiologically relevant rat aortic ring assay, where they showed similar inhibitory effects to semaxanib at 10 μg/mL, confirming that 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones represent a new class of angiogenesis inhibitors.
Synthesis and Preliminary
) is a receptor tyrosine kinase (RTK) and angiogenesis inhibitor approved for the treatment of renal cell carcinomas, gastrointestinal stromal tumours and pancreatic neuroendocrine tumours. A key structural motif retained throughout medicinal chemistry efforts during sunitinib's development was the indoline-2-one group. In the search for new anti-angiogenic scaffolds, we previously reported that non-indoline-2-one-based derivatives of semaxanib (SU5416, a structurally simpler sunitinib predecessor that underwent Phase III trials) are active as angiogenesis inhibitors, indicating that the group is not essential for activity. This report describes the synthesis and structureactivity relationships of another class of non-indoline-2-one angiogenesis inhibitors related to sunitinib/semaxanib; the 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones. A focussed library of 19 analogues was prepared using a simple novel process, wherein commercially available substituted arylacetic acids activated with an amide coupling reagent (HBTU) were reacted with the potassium salt of 3,5-dimethyl-1H-pyrrole-2-carbaldehyde in one-pot. Screening of the library using a cell-based endothelial tube formation assay identified 6 compounds with anti-angiogenesis activity. Two of the compounds were advanced to the more physiologically relevant rat aortic ring assay, where they showed similar inhibitory effects to semaxanib at 10 g/mL, confirming that 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones represent a new class of angiogenesis inhibitors. The indolin-2-one (oxindole) portion was considered crucial for activity of sunitinib 1 and was retained throughout development. Indeed, the structurally simpler indolin-2-one predecessor semaxanib (SU5416) 2 underwent a Phase III clinical trial for advanced colorectal cancer. 6 In recent work, we
showed that in spite of its perceived importance the indolin-2-one moiety is not essential for antiangiogenic activity in this class, demonstrating that ring-opened 3,5-dimethyl-1H-pyrrol-2-yl-2-arylacrylate 3 variants of semaxanib 2 inhibit angiogenesis in a rat aortic ring model. 7 We now report the discovery of a second class of non-indolin-2-one-based angiogenesis inhibitors related to sunitinib 1/semaxanib 2; the 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones 4 ( Figure 1 ). We hypothesised that 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones might possess anti-angiogenic properties due to their structural similarity to sunitinib 1, SU5416 2 and acrylates 3. The hypothesis was tested by developing new chemistry to create a small library of analogues carrying systematic variations at the 2-aryl ring and investigating their structure-activity relationships (SAR). Sporadic reports of 3H-pyrrolizin-3-ones have appeared in the literature but little remains known about their chemistry and biological activity. [8] [9] [10] [11] [12] [13] Complex structures incorporating a 3H-pyrrolizin-3-one-type core have been reported, including tricyclic pyrrolo-indolones, pyrrolo-isoindolones, tetracyclic isoindoloindolones and other polycyclic heterocycles. [14] [15] A number of these are marine natural products or their derivatives. 16 Divergent access to 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones appeared achievable in one-pot from 3,5-dimethyl-1H-pyrrole-2-carbaldehyde 5 and the many commercially available substituted phenylacetic acids. We had previously shown that the K + salt of 5 (generated using KH in THF) is smoothly N-acylated by methyl chloroformate, Employing the method with a systematic series of mono-substituted phenylacetic acid derivatives carrying F, Cl, Br, Me, OCH 3 and NO 2 groups at each of the 2ʹ-, 3ʹ -and 4ʹ -positions similarly provided analogues 7-24 (Scheme 1). While the yields were low to moderate (4-48%) the simple procedure allowed rapid access to useable quantities of pure analogues for the SAR study. Scheme 1. Divergent one-pot synthesis of 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones 6-24. At 100 µg/mL PI-88 reduced % FOV occupancy to 39%. SU5416 2 (synthesised in-house using the literature method) 21 reduced % FOV occupancy to 61% at 1 µg/mL and 10% at 10 µg/mL. Compound (4% FOV occupancy). Compound 6, which showed lower potency than 22 in the endothelial tube formation assay, showed reductions in % FOV occupancy only slightly less than 22 at 10 µg/mL (Figure 4) . In summary, a divergent one-pot synthesis of 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones was developed using commercially available mono-substituted phenylacetic acids and pyrrole aldehyde 5.
Usable quantities of all analogues for the SAR study were obtained but scope remains for improving the yields. Nineteen analogues were synthesised and screened for anti-angiogenesis activity in an endothelial tube formation assay. The 2ʹ-NO 2 analogue 22 was identified as the most potent inhibitor and the unsubstituted parent compound 6 and 2ʹ-fluoro 7, 2ʹ-bromo 13, 2ʹ-methyl 16 and 2ʹ-methoxy 19 derivatives showed activity. In contrast, all 3ʹ-and 4ʹ-substituted analogues were inactive. Compounds properties in a more physiologically relevant context. Both compounds showed robust inhibitory effects at 10 g/mL, confirming 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones as a new class of angiogenesis inhibitors. Further structure-activity studies aimed at identifying more potent inhibitors are warranted. Key targets to pursue would include sunitinib-like analogues, where the basic N,Ndiethylethylenediamine side chain amide of sunitinib is appended at the 6-position of 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones. Profiling the class for activity against a panel of RTKs should provide insights into the mechanism of action of these compounds.
